Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Immunome Inc (IMNM) USD0.0001

Sell:$23.00 Buy:$29.30 Change: $2.24 (8.52%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
Sell:$23.00
Buy:$29.30
Change: $2.24 (8.52%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
Sell:$23.00
Buy:$29.30
Change: $2.24 (8.52%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Immunome Inc. is a biopharmaceutical company utilizing its human memory B cell platform to discover and develop antibody therapeutics. The Company’s primary focus is oncology. Its discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. Its lead oncology program is focused on IL-38. It is engaged in the research and development of the antibody mixture. IMM-BCP-01 is its lead infectious disease discovery program with a focus on SARS-CoV-2.

Contact details

Address:
665 STOCKTON DRIVE, SUITE 300
EXTON
19341
United States
Telephone:
+1 (610) 3213700
Website:
immunome.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IMNM
ISIN:
US45257U1088
Market cap:
$295.95 million
Shares in issue:
10.63 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Rapp
    Chairman of the Board
  • Purnanand Sarma
    President, Chief Executive Officer, Director
  • Scott Dessain
    Co-Founder
  • Diane Marcou
    Interim Chief Financial Officer
  • Michael Morin
    Chief Scientific Officer, Director
  • Matthew Robinson
    Vice President - Research & Development
  • Sandra Stoneman
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.